Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell therapy for autism.

Thomas E Ichim1, Fabio Solano, Eduardo Glenn

  • 1Medistem Laboratories Inc, Tempe, Arizona, USA. thomas.ichim@gmail.com

Journal of Translational Medicine
|June 29, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan.

Journal of translational medicine·2026
Same author

Aspiration to architecture: multi-omics, AI, digital twins, and blockchain for P4 medicine.

Journal of translational medicine·2026
Same author

N-Acetylcysteine is associated with changes in functional connectivity in patients with Parkinson's disease.

Parkinsonism & related disorders·2026
Same author

Reduction of solid tumors by senescent cell immunization.

Journal of translational medicine·2025
Same author

Reversing coma by senolytics and stem cells: the future is now.

Journal of translational medicine·2025
Same author

A Georgian tragedy of madness and mystery: Louisa, the 'maid of the haystack'.

History of psychiatry·2025

This study proposes using mesenchymal stem cells (MSC) and cord blood CD34+ cells together to treat autism spectrum disorder (ASD). These cells may address immune issues and poor blood flow associated with ASD.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Autism spectrum disorders (ASD) are increasingly prevalent neurodevelopmental conditions.
  • Immune abnormalities and neural hypoperfusion are consistently observed in individuals with autism.
  • These physiological alterations correlate with ASD symptomatology, suggesting a potential causative role.

Purpose of the Study:

  • To explore the potential therapeutic benefits of combining Mesenchymal Stem Cells (MSC) and cord blood CD34+ cells for treating autism spectrum disorder (ASD).

Main Methods:

  • Mesenchymal stem cells (MSC) are currently in advanced clinical trials for immune dysregulation conditions.
  • Cord blood CD34+ cells are recognized for their potent angiogenic properties, showing efficacy in ischemia models.

Related Experiment Videos

  • Anecdotal reports suggest positive responses in autistic children treated with cord blood CD34+ cells.

    • Main Results:

    • The proposed combination therapy leverages the immune-modulating effects of MSC and the angiogenic potential of CD34+ cells.
    • This synergistic approach aims to address the underlying neurophysiological deficits in ASD.

    Conclusions:

    • The combined administration of MSC and cord blood CD34+ cells presents a promising novel therapeutic strategy for autism spectrum disorder.
    • Further research and clinical trials are warranted to validate the efficacy and safety of this combined treatment approach.